These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35131452)

  • 21. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
    Lewis KD; Larkin J; Ribas A; Flaherty KT; McArthur GA; Ascierto PA; Dréno B; Yan Y; Wongchenko M; McKenna E; Zhu Q; Mun Y; Hauschild A
    Br J Cancer; 2019 Oct; 121(7):522-528. PubMed ID: 31417188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Gerard Duhard P; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2023 Dec; 24(12):e461-e471. PubMed ID: 37459873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
    Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
    Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
    Simeone E; Scognamiglio G; Capone M; Giannarelli D; Grimaldi AM; Mallardo D; Madonna G; Curvietto M; Esposito A; Sandomenico F; Sabbatino F; Bayless NL; Warren S; Ong S; Botti G; Flaherty KT; Ferrone S; Ascierto PA
    J Transl Med; 2021 Jan; 19(1):17. PubMed ID: 33407577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
    Hieken TJ; Nelson GD; Flotte TJ; Grewal EP; Chen J; McWilliams RR; Kottschade LA; Yang L; Domingo-Musibay E; Dronca RS; Yan Y; Markovic SN; Dimou A; Montane HN; Erskine CL; Piltin MA; Price DL; Khariwala SS; Hui J; Strand CA; Harrington SM; Suman VJ; Dong H; Block MS
    Nat Commun; 2024 Feb; 15(1):1430. PubMed ID: 38365756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF
    Ascierto PA; Lewis KD; Di Giacomo AM; Demidov L; Mandalà M; Bondarenko I; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Simmons B; Ye C; Hooper G; Wongchenko MJ; Goodman GR; Yan Y; Schadendorf D
    Ann Oncol; 2020 Jan; 31(1):153-159. PubMed ID: 31912791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with
    Yan Y; Wongchenko MJ; Robert C; Larkin J; Ascierto PA; Dréno B; Maio M; Garbe C; Chapman PB; Sosman JA; Shi Z; Koeppen H; Hsu JJ; Chang I; Caro I; Rooney I; McArthur GA; Ribas A
    Clin Cancer Res; 2019 Jun; 25(11):3239-3246. PubMed ID: 30824584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF
    Sandhu S; Atkinson V; Cao MG; Medina T; Rivas AS; Menzies AM; Caro I; Roberts L; Song Y; Yan Y; Guo Y; Xue C; Long GV
    Eur J Cancer; 2023 Jan; 178():180-190. PubMed ID: 36455412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
    Meyer N; Pérol D; Duval-Modeste AB; El Adaoui L; Lelarge Y; Niarra R; Mateus C
    Melanoma Res; 2022 Aug; 32(4):269-277. PubMed ID: 35635532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
    J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.